CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer

Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFRi) are approved for treating EGFR-mutant lung adenocarcinoma (LUAD), emergence of acquired resistance limits their clinical benefits. Several mechanisms for acquired resistance to EGFRi in LUAD have been identified; how...

Descripción completa

Detalles Bibliográficos
Autores principales: Bugide, Suresh, Edwards, Yvonne J. K., Gupta, Romi, Green, Michael R., Wajapeyee, Narendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942844/
https://www.ncbi.nlm.nih.gov/pubmed/36652476
http://dx.doi.org/10.1073/pnas.2218118120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942844/
https://www.ncbi.nlm.nih.gov/pubmed/36652476
http://dx.doi.org/10.1073/pnas.2218118120

Ejemplares similares